“药茅”恒瑞医药“豪掷”60亿买理财 上半年净利增长近三成

Core Insights - Heng Rui Medicine reported a revenue of 15.76 billion yuan for the first half of 2025, representing a year-on-year growth of 15.9% [1] - The net profit attributable to shareholders reached 4.45 billion yuan, with a year-on-year increase of 29.7% [1] - The company maintained a high level of R&D investment, totaling 3.871 billion yuan, with 3.228 billion yuan classified as expensed R&D [2] Financial Performance - Revenue from innovative drug sales and licensing amounted to 9.561 billion yuan, accounting for 60.66% of total revenue [2] - Innovative drug sales revenue specifically was 7.570 billion yuan [2] - The company received significant upfront payments from Merck Sharp & Dohme (200 million USD) and IDEAYA (75 million USD), which positively impacted profits [2] Capital Management - Heng Rui Medicine plans to use up to 6 billion yuan of idle funds for entrusted wealth management, ensuring it does not affect normal operations [3] - The company announced a share buyback plan, intending to repurchase A-shares with a total fund of no less than 1 billion yuan and no more than 2 billion yuan, at a maximum price of 90.85 yuan per share [3] - As of the end of Q2, the total assets of Heng Rui Medicine were 62.894 billion yuan, a 25.4% increase from the previous year [4] Market Position - The company's stock closed at 62.85 yuan per share, with a total market capitalization of 417.148 billion yuan [4] - The net assets attributable to shareholders were 58.465 billion yuan, reflecting a year-on-year growth of 28.4% [4]